September 2026 FDA Recall Imaavy by J&j Innovative Medicine
D-0016-2027 - Presence of particulate matter.

This Class II drug recall was voluntarily initiated by J&j Innovative Medicine on September 23, 2026 for the product Imaavy. The FDA reported the reason for recall as presence of particulate matter.. The product was distributed in OH and the recall is currently ongoing.

Recall Number: D-0016-2027

Reason for Recall
Presence of particulate matter.
Initiated
09-23-2026
Reported
10-14-2026
Quantity
49 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
J&J INNOVATIVE MEDICINE
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01

Batch or Lot Expiration Information

Lot# Lot JNYJ1208; Exp. 10/30/2027

Affected Packages Involved in this Recall